Feed aggregator

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

World Pharma News - Tue, 05/07/2024 - 10:00
Novartis announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need.

The transaction bolsters the Novartis RLT pipeline and expands the company's research infrastructure and clinical supply capabilities, supporting Novartis strategic priorities in oncology and RLT platform innovation.

Participants of pioneering CRISPR gene editing trial see vision improve

World Pharma News - Mon, 05/06/2024 - 10:00
About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published today in the New England Journal of Medicine.

"This trial shows CRISPR gene editing has exciting potential to treat inherited retinal degeneration," said Mark Pennesi, M.D., Ph.D., a corresponding author on the paper, an ophthalmologist and Oregon Health & Science University's lead scientist for the Phase 1/2 BRILLIANCE trial.

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer

Biospace news - Sat, 05/04/2024 - 02:00
AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer 4/5/2024

Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials

Biospace news - Sat, 05/04/2024 - 02:00
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials 4/5/2024

Networking, ADCs and Early Science on the Agenda at AACR 2024

Biospace news - Sat, 05/04/2024 - 02:00
Networking, ADCs and Early Science on the Agenda at AACR 2024 4/5/2024

US National Security, China and Biotechnology in 2024

Biospace news - Sat, 05/04/2024 - 02:00
US National Security, China and Biotechnology in 2024 4/5/2024

Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS

Biospace news - Sat, 05/04/2024 - 02:00
Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS 4/5/2024

FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy

Biospace news - Sat, 05/04/2024 - 02:00
FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy 4/5/2024

Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters

Biospace news - Sat, 05/04/2024 - 02:00
Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters 4/5/2024

Novartis to File for Pluvicto Label Expansion After Promising Phase III Data

Biospace news - Sat, 05/04/2024 - 02:00
Novartis to File for Pluvicto Label Expansion After Promising Phase III Data 4/5/2024

Drug targeting RNA modifications shows promise for treating neuroblastoma

World Pharma News - Fri, 05/03/2024 - 10:00
Neuroblastoma is a common pediatric cancer that originates in developing nerve cells outside the brain. While increasingly intensive treatments have improved the survival of patients with high-risk neuroblastoma, currently more than 40% of patients do not survive.

New research from the University of Chicago shows the potential for a promising new approach to treating neuroblastoma by targeting RNA modifications associated with the disease.

Scientists track 'doubling' in origin of cancer cells

World Pharma News - Thu, 05/02/2024 - 10:00
Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.

The findings, published May 3 in Science, reveal what goes wrong when a group of molecules and enzymes trigger and regulate what's known as the "cell cycle," the repetitive process of making new cells out of the cells' genetic material.

Possible alternative to antibiotics produced by bacteria

World Pharma News - Wed, 05/01/2024 - 10:00
Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the German Center for Infection Research (DZIF) have discovered a new so-called lantibiotic, namely epilancin A37. It is produced by staphylococci that colonize the skin and acts specifically against their main competitors there, the corynebacteria.

Kaposi sarcoma discovery could facilitate drug development

World Pharma News - Tue, 04/30/2024 - 10:00
Researchers at UNC Lineberger Comprehensive Cancer Center, after decades of research efforts, have developed a mouse model of Kaposi sarcoma that could be key to the development of new drugs to treat the disease. Kaposi sarcoma is a cancer that is the most common cancer in people living with HIV.

The findings appeared in Cell Host & Microbe.

Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B

Biospace news - Tue, 04/30/2024 - 02:00
Lilly Touts 26% Q1 Revenue Growth on Strong Mounjaro Sales, Raises Full-Year Guidance by $2B 4/30/2024

Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer

Biospace news - Tue, 04/30/2024 - 02:00
Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer 4/30/2024

Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group

Biospace news - Tue, 04/30/2024 - 02:00
Enlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences Group 4/30/2024

J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program

Biospace news - Tue, 04/30/2024 - 02:00
J&J, BMS Lose Challenges to Medicare Drug Price Negotiation Program 4/30/2024

AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win

Biospace news - Tue, 04/30/2024 - 02:00
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win 4/30/2024

Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership

Biospace news - Tue, 04/30/2024 - 02:00
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership 4/30/2024